Experimental Hematology
Volume 34, Issue 11 , Pages 1443-1450, November 2006

Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature

Division of Hematology/Oncology, University of Nevada, School of Medicine, Veterans Affairs Medical Center, Washoe Medical Center, Reno, Nev., USA

Received 21 September 2005; received in revised form 24 May 2006; accepted 29 June 2006.

Objective

Given the potential to limit cost, we conducted a pilot study evaluating delayed, low-dose granulocyte colony-stimulating factor (G-CSF) following chemotherapy for the procurement of peripheral blood progenitor cells (PBPCs) for autologous transplantation and reviewed the relevant literature.

Patients and methods

Twenty-eight patients with various malignancies received cyclophosphamide 4 gm/m2 and paclitaxel 170 mg/m2 followed by G-CSF 300 μg/d or 480 μg/d starting day +5 until two to four daily large volume leukapheresis yielded ≥5.0 × 106 CD34+ cells. We searched MEDLINE, Pubmed, and EMBASE databases from 1990 to the present to identify papers on PBPC procurement using delayed G-CSF (starting day +4 or later) following chemotherapy.

Results

G-CSF was administered for a median of 9 days at an average cost of $1260 USD per 70-kg patient. Collection was initiated at a median of 12 days after chemotherapy. A median 2.5 (range 2–4) apheresis were performed yielding an average daily CD34+ collection of 6.9 × 106 /kg (range 0.35–56.7). After one apheresis, 82% and 57% of patients collected ≥2.5 × 106/kg and ≥5.0 × 106/kg, respectively. Ultimately, 89% collected ≥5.0 × 106/kg. Febrile neutropenia and catheter-related infection developed in five and two patients, respectively. All patients proceeded to transplantation and engrafted successfully with a median of 14.9 × 106/kg (range 1.05–113) cells infused. Eleven published reports were identified involving 590 patients of whom 498 received G-CSF at a dose range of 250 μg/d to 10 μg/kg/d starting day +4 to 15 for a period of 4 to 9 days for PBPC procurement. Among these reports, 62 to 100% and 33 to 96% of patients collected ≥2 to 2.5 × 106 and ≥5.0 × 106 CD34+ cells, respectively.

Conclusion

The use of delayed, low-dose G-CSF plus chemotherapy for stem cell mobilization was feasible and provides further evidence supporting this potentially cost-effective strategy. A review of the literature supports our findings and emphasizes the need for larger studies to address this issue.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0301-472X(06)00457-7

doi:10.1016/j.exphem.2006.06.022

Experimental Hematology
Volume 34, Issue 11 , Pages 1443-1450, November 2006